Not necessarily the strongest absolute response. The most rational target could be the one where the difference in efficacy between Coramsine and the current best treatment is greatest. This presumably needs also to be blended with market potential to arrive at the optimal target.
- Forums
- ASX - By Stock
- SBP
- genentech up $11 billion
SBP
solbec pharmaceuticals limited
genentech up $11 billion, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Currently unlisted public company.
The Watchlist
VMM
VIRIDIS MINING AND MINERALS LIMITED
Rafael Moreno, CEO
Rafael Moreno
CEO
SPONSORED BY The Market Online